Ligand Pharmaceuticals Incorporated
LGND
$193.03
-$2.07-1.06%
NASDAQ
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 142.43% | 5.06% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 142.43% | 5.06% | |||
| Cost of Revenue | 161.98% | -82.75% | |||
| Gross Profit | 137.57% | 497.39% | |||
| SG&A Expenses | 41.00% | 7.31% | |||
| Depreciation & Amortization | -1.95% | 0.01% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 61.88% | -53.77% | |||
| Operating Income | 456.56% | 126.51% | |||
| Income Before Tax | 1,157.57% | 122.37% | |||
| Income Tax Expenses | 274.28% | 182.49% | |||
| Earnings from Continuing Operations | 2,319.50% | 111.42% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 2,319.50% | 111.42% | |||
| EBIT | 456.56% | 126.51% | |||
| EBITDA | 255.07% | 162.84% | |||
| EPS Basic | 2,288.36% | 111.34% | |||
| Normalized Basic EPS | 451.44% | 127.01% | |||
| EPS Diluted | 2,266.67% | 110.85% | |||
| Normalized Diluted EPS | 439.55% | 126.20% | |||
| Average Basic Shares Outstanding | 1.30% | 0.71% | |||
| Average Diluted Shares Outstanding | 3.53% | 3.83% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||